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Abstract
Purpose. The aim of this paper was to assess the growth in the unaffected lower limb of children who had received
chemotherapy for a malignant primary bone tumour around the knee.
Subjects/methods. Following diagnosis, all children (45, of which 32 were boys and 13 were girls) were staged. If
limb-salvage surgery was thought appropriate, measured radiographs of both legs was performed, the bone age was
estimated and the expected growth in the femur and tibia was calculated according to Tupman. These procedures were
repeated at follow-up and the data plotted. Regression and correlation coef® cients were also calculated.
Results. The observed regression line in boys was almost identical to Tupman’s curve. However, the observed growth in
girls was larger than the expected growth.
Discussion. It is recommended that the regression lines presented here are used in the calculation of the expected growth
in the lower limb of children who have received chemotherapy for a malignant primary bone tumour, especially in girls.
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Introduction
Neo-adjuvant chemotherapy has greatly improved
the survival in children with malignant primary bone
tumours. The overall survival in patients with osteo-
sarcoma is nowadays 64%.
1
Improvements in diagnostic imaging, surgical
technique, biomedical engineering and survival have
made limb-salvage surgery in children possible. One
limb-salvage option for children with a malignant
primary bone tumour around the knee is replace-
ment with a custom-made extensible endoprosthetic
replacement.
2± 6 Our centre has performed extensible
endoprosthetic replacements for primary bone tu-
mours around the knee since 1976.
In order to manufacture the extensible endopros-
thetic replacement, it is necessary to have an esti-
mate of the expected growth in the lower limb. Our
centre has used data provided by Tupman
7 to calcu-
late this growth. However, these data are based on a
normal population of children.
Fraumeni
8 reported that children with osteosar-
coma are taller at the time of diagnosis than con-
trols. However, others
9,10 did not ® nd such a
relation.
Glasser et al.
9 showed that children with malig-
nant primary bone tumours had a marked retar-
dation in growth during the year of cytotoxic
chemotherapy. They concluded that ® nal height
might be affected, but to a small degree.
We could ® nd no reports in the literature provid-
ing information about the growth in the lower limb
of children who have received chemotherapy. The
aim of this study was to assess the growth in the
lower limb of children who had chemotherapy for a
malignant primary bone tumour.
Subjects and methods
Following the diagnosis of a malignant primary
bone tumour of the distal femur or proximal tibia,
all children were fully staged. This included a radio-
graph of the lesion, magnetic resonance imaging
(MRI) or computed tomography (CT) of the lesion,
a bone scan and a CT scan of the chest.
If the patient was thought to be suitable for
limb-salvage surgery, measured radiographs of both
legs were also performed. The bone age was also
estimated according to the Greulich and Pyle
method.
11 With the bone age, the expected growth
in the femur and tibia was calculated according to
Tupman.
7
All patients received chemotherapy in a neo-
adjuvant setting according to the then current
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Fig. 1. Growth at the latest time of follow-up in the femur and tibia in 45 children who received chemotherapy for a malignant primary
bone tumour around the knee. Children who were skeletally mature at review are indicated by 31 and children who were immature by
s . Tupman’s curve is shown in grey. The dotted lines indicate the proximal and distal physeal growth as calculated from the regression
line. The formula of the regression line and the correlation coef® cient (r) are shown in the box.
protocol. No patients received radiotherapy to the
extremities. Limb-salvage surgery was performed
and the patients were followed up in the outpatient
clinic.
At the time of review, all patients had measured
radiographs of both legs and their bone age esti-
mated. The growth in the unaffected (normal) leg
was calculated. As in Tupman’s
7 review, the femur
was measured from the top of the femoral head to
the medial condyle. The tibia was measured from
the top of the tibial spine to the tip of the medial
malleolus.
Patients who were skeletally immature at review
had the expected growth at the time of review added
to the measured growth.
The data were plotted on a graph and super-
imposed on Tupman’s
7 curve. The regression
coef® cients were calculated by means of the least
square method and the regression line was plotted
in the ® gure. Correlation coef® cients were also
calculated.
In order to plan limb-salvage surgery, it is ex-
tremely helpful to have an estimate of the expected
growth in the proximal and distal physis of the
affected bone. The growth in the proximal femoral
physis has been reported
7 as 30% and the growth in
the distal femoral physis as 70% of the total femoral
growth. Similarly, the proximal tibial growth is 55%
and the distal tibial growth 45% of the total growth
in that bone.
7 With the aid of these ® gures, re-
gression lines for the proximal and distal physeal
growth in the femur and tibia were also calculated
and added to the ® gure.
Results
Between 1976 and 1992, our centre performed 106
extensible endoprosthetic replacements in childrenGrowth following chemotherapy 77
with a malignant primary bone tumour around the
knee. Of these patients, 39 died.
Patients were excluded if the follow-up was less
than 1.5 years or if insuf® cient radiographs were
available to assess the growth. These criteria left 45
children in the study. There were 32 boys and 13
girls. The chronological age at diagnosis was on
average 11.2 years (range 6.5± 15.3 years) and the
mean bone age was 10.6 years (range 6± 14 years).
All patients were fully staged as described earlier
and received neo-adjuvant chemotherapy according
to the relevant treatment protocol. In 37 cases the
diagnosis was osteosarcoma, in seven cases, Ewing’s
sarcoma and malignant ® brous histiocytoma in the
remaining patient. There were 29 patients who had
a distal femoral tumour. The remaining 16 patients
had a proximal tibial tumour. The left side was
affected in 23 cases and the right side in 22 cases.
The average follow-up was 4.5 years in both boys
(range 2.1± 7.9 years) and girls (range 1.7± 11.1
years). On average, the chronological age at follow-
up was 16.0 years in boys (range 12.4± 20.8 years)
and 14.7 years in girls (range 11.1± 22.8 years).
Figure 1 shows the femoral and tibial growth that
had occurred in boys and girls at the latest follow-up
plotted against the bone age at diagnosis. There
were two boys who had identical measurements,
which explains why only 31 points are visible in the
graphs for boys.
There were 17 boys (53%) and seven girls (54%)
who were skeletally mature at latest time of follow-
up (indicated by 31 ); the remaining 21 children were
skeletally immature (indicated by s ).
The regression lines and correlation coef® cients
are shown in the ® gure. Furthermore, regression
lines for the proximal and distal growth in the femur
and tibia were calculated as described earlier and
added to the ® gure. Tupman’s
7 original curve is also
shown.
Discussion
The observed regression line in boys is almost iden-
tical to Tupman’s
7 curve. However, in girls the
observed growth is larger than the expected growth.
Although there were considerably less girls than
boys in this study, virtually all girls had a growth
that was equal to or larger than expected. Further-
more, the correlation coef® cients are high. It seems
therefore likely that the regression line in girls is a
realistic indicator of growth. The reason for the sex
difference remains unclear.
Tupman
7 performed his study in 1962. There-
fore, it is possible that his data are out of date.
Unfortunately, more recent data are not available.
However, comparison with our regression lines indi-
cates that growth following chemotherapy is inde-
pendent of skeletal maturity prior to chemotherapy
treatment. Furthermore, there does not seem to be
a longlasting effect of chemotherapy on longitudinal
growth in the lower limb.
A longer follow-up time is unlikely to in¯ uence
the observed regression lines signi® cantly, since
53% of the children were skeletally mature at the
time of review and the correlation coef® cients are
high.
In conclusion, we recommend that these new
regression lines are used in the calculation of the
expected growth in the lower limb in children who
received cytotoxic chemotherapy for a malignant
primary bone tumour. This seems especially import-
ant in girls.
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